CDKN1B Antibody

What is CDKN1B and why is it significant in cellular research?

CDKN1B (Cyclin-Dependent Kinase Inhibitor 1B), also known as p27KIP1, is a key cell cycle regulatory protein that functions as a negative regulator of G1 progression. This 27 kDa protein inhibits cyclin-dependent kinase (CDK) activation and the kinase activity of assembled cyclin-CDK complexes, thereby controlling cell proliferation. CDKN1B is encoded by the CDKN1B gene mapped to chromosome 12p13.1 in humans . Beyond cell cycle regulation, CDKN1B is involved in cell differentiation, migration, and apoptosis. Its tumor suppressor function makes it particularly important in cancer research, as low p27 expression has been associated with unfavorable prognosis in various cancers including renal cell carcinoma, breast carcinomas, and non-small-cell lung carcinoma . CDKN1B has also been proposed to function as a mediator of TGF-β induced G1 arrest .

What applications are CDKN1B antibodies commonly used for in laboratory research?

CDKN1B antibodies are versatile research tools applicable across multiple experimental methodologies:

These antibodies enable researchers to study CDKN1B expression levels, subcellular distribution, and interactions with binding partners across different experimental setups . The specific application determines which antibody characteristics (monoclonal vs polyclonal, host species, epitope) are most important for successful detection.

How should Western blot protocols be optimized for CDKN1B detection?

For optimal CDKN1B detection via Western blotting, follow these methodological recommendations based on validated protocols:

• Sample preparation: Load approximately 30 μg of protein per lane

• Gel selection: Use 5-20% SDS-PAGE gel

• Electrophoresis conditions: Run at 70V (stacking gel) followed by 90V (resolving gel) for 2-3 hours

• Transfer conditions: Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes

• Blocking: Use 5% non-fat milk/TBS for 1.5 hours at room temperature

• Primary antibody: Incubate with anti-CDKN1B antibody at 0.5 μg/mL overnight at 4°C

• Washing: Perform 3 washes with TBS-0.1% Tween, 5 minutes each

• Secondary antibody: Incubate with appropriate HRP-conjugated secondary antibody at 1:5000 dilution for 1.5 hours at room temperature

• Detection: Develop using Enhanced Chemiluminescent detection (ECL) system

Note that CDKN1B typically appears at 27 kDa, though its calculated molecular weight is approximately 22 kDa . Under reducing conditions, ubiquitinated CDKN1B appears as multiple higher molecular weight bands .

What controls should be included when working with CDKN1B antibodies?

Rigorous experimental design requires appropriate controls when using CDKN1B antibodies:

• Positive controls:

  • Cell lines with confirmed CDKN1B expression (e.g., HeLa, MCF-7)

  • Recombinant CDKN1B protein

• Negative controls:

  • CDKN1B knockout samples (if available)

  • Tissues/cells known to express minimal CDKN1B

• Technical controls:

  • Secondary antibody-only control to assess background

  • Isotype control antibody to evaluate non-specific binding

  • Blocking peptide competition (pre-incubate antibody with immunizing peptide)

Including knockout-validated antibodies dramatically increases confidence in experimental results. Several commercial antibodies like CAB16633 are specifically validated against knockout samples .

What factors affect reproducibility when using CDKN1B antibodies?

Several critical factors influence reproducibility in CDKN1B antibody-based experiments:

• Antibody selection: Different antibodies recognize different epitopes. For example, some antibodies target the N-terminal region (AA 1-100), while others target the C-terminal region (AA 150-198) . Epitope accessibility varies depending on protein conformation and modifications.

• Sample preparation: CDKN1B stability is affected by:

  • Fixation method (for IHC/IF)

  • Lysis buffer composition

  • Protease/phosphatase inhibitors

  • Storage conditions

• Post-translational modifications: CDKN1B undergoes extensive modifications including phosphorylation and ubiquitination that can mask epitopes .

• Technical variables:

  • Antibody lot-to-lot variation

  • Incubation times and temperatures

  • Detection systems

To maximize reproducibility, carefully document all experimental conditions and use recombinant monoclonal antibodies when possible, as they typically offer greater consistency than polyclonal antibodies .

What are common troubleshooting strategies for CDKN1B antibody experiments?

When encountering issues with CDKN1B antibody experiments, consider these methodological solutions:

For Western blots specifically, remember that CDKN1B often appears slightly higher (27 kDa) than its calculated molecular weight (22 kDa) .

How do post-translational modifications affect CDKN1B antibody recognition?

CDKN1B undergoes extensive post-translational modifications that significantly impact antibody recognition:

• Phosphorylation sites:

  • Threonine 187: CDK-dependent phosphorylation targeting CDKN1B for degradation

  • Threonine 198 (human)/197 (mouse): C-terminal phosphorylation affecting protein stability as demonstrated in the T197A knock-in model

  • Serine 10: Phosphorylation affecting nuclear export

• Ubiquitination: CDKN1B can be polyubiquitinated, appearing as multiple higher molecular weight bands in Western blots. Under reducing conditions, these ubiquitinated forms are more readily detected than under non-reducing conditions .

• Methodological considerations:

  • Epitope masking: Modifications can obscure antibody binding sites

  • Conformation changes: Modifications alter protein structure

  • Subcellular redistribution: Modifications affect localization

When studying specific modified forms, use modification-specific antibodies or combine immunoprecipitation with modification-specific detection. The choice of antibody epitope is critical—antibodies targeting regions prone to modifications may show variable binding depending on the modification state .

What methodological approaches are effective for studying CDKN1B degradation pathways?

CDKN1B degradation occurs through multiple pathways that require specific experimental approaches:

• Proteasomal degradation:

  • Proteasome inhibitors: The T197A knock-in model demonstrates that bortezomib treatment rescues hyperplasia by preventing CDKN1B degradation

  • Ubiquitination detection: Immunoprecipitate CDKN1B followed by Western blot using anti-ubiquitin antibodies under both reducing and non-reducing conditions

  • Half-life measurement: Cycloheximide chase assays can quantify CDKN1B stability differences

• Autophagy-mediated degradation:

  • Autophagy inhibitors: Use compounds like chloroquine or bafilomycin A1

  • Subcellular fractionation: CDKN1B colocalizes with autophagosome marker LC3-II in fractions 4-8 during autophagy

  • Autophagy receptor interactions: CDKN1B associates with the autophagy receptor SQSTM1/p62

• Genetic models:

  • The T197A knock-in model provides insights into CDKN1B stability regulation through the C-terminal threonine residue

  • Genetic deletion of one allele of CDKN1B in autophagy-deficient T cells restores proliferative capability

These methods can reveal how different cellular conditions affect CDKN1B turnover and how this regulation impacts cell cycle progression and proliferation .

How can researchers effectively analyze CDKN1B in immune cells, particularly T lymphocytes?

Studying CDKN1B in immune contexts presents unique methodological challenges:

• T cell-specific considerations:

  • Autophagy regulates CDKN1B levels in naïve T cells and selectively degrades CDKN1B after TCR stimulation

  • CDKN1B accumulates in autophagy-deficient naïve T cells and cannot be degraded after TCR stimulation

  • The inability to downregulate CDKN1B impairs T cell proliferation and S-phase entry

• Experimental approaches:

  • Flow cytometry: Combine CDKN1B staining with T cell markers and cell cycle analysis

  • Immunoprecipitation: CDKN1B can be isolated from normal T cells before and after TCR activation

  • Western blot analysis under both reducing and non-reducing conditions reveals different CDKN1B forms

  • Cell cycle phase correlation: Synchronize cells and analyze CDKN1B levels at different cell cycle stages

• Functional analysis:

  • Genetic models: CDKN1B knockout or heterozygous models in T cells

  • Primary immune response: The Listeria monocytogenes (LM) infection model reveals impaired primary immune responses in autophagy-deficient CD8+ T cells due to CDKN1B accumulation

These approaches allow researchers to understand how CDKN1B regulation specifically affects immune cell function and proliferation in response to various stimuli .

What strategies should be employed to study CDKN1B protein-protein interactions?

CDKN1B functions through numerous protein interactions that can be studied using these methodological approaches:

• Co-immunoprecipitation (Co-IP):

  • Select antibodies that don't disrupt complexes - some CDKN1B antibodies can co-precipitate CDK4 in complex with CDKN1B

  • Use mild lysis conditions to preserve protein complexes

  • Consider crosslinking to capture transient interactions

  • Both forward and reverse Co-IP provide stronger evidence

• Proximity-based methods:

  • Proximity Ligation Assay (PLA): Detects interactions within 40nm in fixed cells

  • FRET/FLIM: For studying interactions in living cells with nanometer resolution

  • BioID or APEX2: For identifying interactome in living cells

• Structural considerations:

  • The N-terminal portion of CDKN1B binds to cyclins

  • The C-terminal region binds to CDKs

  • Different antibodies may disrupt specific interactions

• Verification strategies:

  • Mutational analysis: Test interaction domains

  • Cell cycle dependence: Assess interactions at different cell cycle phases

  • Competition assays: Use peptides to disrupt specific interactions

These methods help elucidate how CDKN1B interactions change under different cellular conditions and how these changes affect its function as a cell cycle regulator .

How should researchers approach CDKN1B immunohistochemistry in cancer tissues?

CDKN1B immunohistochemistry in cancer tissues requires careful methodological consideration:

• Tissue preparation and antigen retrieval:

  • Formalin-fixed paraffin-embedded (FFPE) tissues require proper antigen retrieval

  • For CDKN1B detection, enzyme antigen retrieval has been successfully used

  • Optimal antibody dilutions typically range from 1:50-1:200 for IHC applications

• Scoring and interpretation:

  • Nuclear vs. cytoplasmic staining: CDKN1B can localize to both compartments, with different functional implications

  • Quantitative assessment: Use digital image analysis for objective scoring

  • Consider heterogeneity: Intratumoral variation in CDKN1B expression is common

• Prognostic significance:

  • Low CDKN1B expression correlates with unfavorable prognosis in multiple cancer types including renal cell carcinoma, breast carcinomas, non-small-cell lung carcinoma, and hepatocellular carcinoma

  • CDKN1B subcellular localization (nuclear vs. cytoplasmic) may have independent prognostic value

• Validation approaches:

  • Parallel methods: Confirm IHC findings with Western blot or mRNA analysis

  • Multiple antibodies: Use antibodies targeting different epitopes

  • Controls: Include positive and negative control tissues in each run

These considerations help ensure reliable assessment of CDKN1B status in cancer tissues for both research and potential clinical applications .

What approaches enable accurate quantification of CDKN1B levels in experimental systems?

Precise quantification of CDKN1B requires appropriate methodological strategies:

• Western blot quantification:

  • Normalization: Use appropriate loading controls (β-actin, GAPDH)

  • Standard curves: Include recombinant CDKN1B protein standards

  • Multiple antibodies: Cross-validate with antibodies targeting different epitopes

  • Consider all CDKN1B forms: Account for post-translationally modified forms

• Flow cytometry:

  • Standardization: Use calibration beads for consistent measurements

  • Controls: Include isotype controls and CDKN1B-negative samples

  • Permeabilization optimization: Critical for accessing intracellular CDKN1B

  • Multiparameter analysis: Correlate CDKN1B levels with cell cycle phases

• Immunofluorescence quantification:

  • Z-stack imaging: Capture the entire cell volume

  • Background subtraction: Critical for accurate measurement

  • Region-specific quantification: Measure nuclear and cytoplasmic compartments separately

  • Reference standards: Include calibration samples in each experiment

• ELISA and other quantitative approaches:

  • Standard curves: Establish with recombinant protein

  • Sample preparation standardization: Ensure consistent extraction efficiency

  • Antibody validation: Confirm specificity and linear detection range

These quantitative approaches provide reliable measurements of CDKN1B levels for comparative analysis across experimental conditions and improve reproducibility of results .